Compare LMT & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMT | BMY |
|---|---|---|
| Founded | 1912 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.9B | 123.7B |
| IPO Year | 1995 | N/A |
| Metric | LMT | BMY |
|---|---|---|
| Price | $627.72 | $57.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 16 |
| Target Price | ★ $591.00 | $61.81 |
| AVG Volume (30 Days) | 1.2M | ★ 9.8M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | 2.16% | ★ 4.25% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 21.49 | N/A |
| Revenue | ★ $75,048,000,000.00 | N/A |
| Revenue This Year | $6.49 | N/A |
| Revenue Next Year | $4.88 | N/A |
| P/E Ratio | $29.63 | ★ $17.26 |
| Revenue Growth | ★ 5.64 | N/A |
| 52 Week Low | $410.11 | $42.52 |
| 52 Week High | $692.00 | $62.89 |
| Indicator | LMT | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 43.26 |
| Support Level | $594.44 | $56.45 |
| Resistance Level | $646.59 | $62.47 |
| Average True Range (ATR) | 14.88 | 1.27 |
| MACD | -0.54 | -0.04 |
| Stochastic Oscillator | 64.86 | 23.20 |
Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Aeronautics is Lockheed's largest segment, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, mainly encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.